ALKS — Recent News Coverage
All news mentioning ALKS in ESEN's AI-graded feed
News stories with ALKS as an affected ticker. Each article is graded by ESEN AI for impact level and direction (up/down/flat) on ALKS. See /coverage/ALKS for the 30-day aggregate.
INSIDERMONKEY.COM
·
2026-08-11
NEUTRAL
NEUTRAL
CORR0.42
Could Alkermes plc (ALKS) Stock Rebound After Investors Look Beyond Near-Term Profit Pressure?
$ALKS
◈ ESEN AI
Alkermes (ALKS) experienced a 5% single-day decline following its Q2 2026 earnings release, reflecting near-term market disappointment with financial performance. The sell-off suggests investors are repricing near-term …
FINANCE.YAHOO.COM
·
2026-08-11
NEUTRAL
NEUTRAL
CORR0.45
Could Alkermes plc (ALKS) Stock Rebound After Investors Look Beyond Near-Term Profit Pressure?
$ALKS
◈ ESEN AI
Alkermes (ALKS) delivered a mixed earnings print that highlights the tension between operational momentum and valuation reset dynamics. The 27% year-over-year revenue acceleration to $496.0 million—driven primarily by $…
SEEKINGALPHA
·
2026-08-06
NEUTRAL
NEUTRAL
CORR0.15
Tarsus Pharmaceuticals to buy Alkeus Pharmaceuticals
$TARS
$ALKS
◈ ESEN AI
Tarsus Pharmaceuticals has announced an acquisition of Alkeus Pharmaceuticals, a consolidation move within the biopharmaceutical sector. This transaction represents typical M&A activity in the pharmaceutical space, wher…
SEEKINGALPHA.COM
·
2026-07-28
NEUTRAL
NEUTRAL
CORR0.35
Alkermes expects Q3 2026 total revenues of $450M-$470M as CEO transition and orexin readouts approach (NASDAQ:ALKS)
$ALKS
◈ ESEN AI
Alkermes (ALKS) provided Q3 2026 revenue guidance of $450M–$470M during its Q2 earnings call, framing a period marked by operational transitions and clinical pipeline catalysts. The guidance itself represents standard f…
SEEKINGALPHA.COM
·
2026-07-28
NEUTRAL
NEUTRAL
CORR0.42
Alkermes plc (ALKS) Q2 2026 Earnings Call Transcript
$ALKS
◈ ESEN AI
Alkermes plc (ALKS) released Q2 2026 earnings results via earnings call on July 28, 2026. The company's earnings call transcript represents a standard quarterly disclosure event where management discusses financial perf…
THEHINDUBUSINESSLINE.COM
·
2026-07-06
NEUTRAL
BULLISH
CORR0.32
Granules India gets key US advantage for Generic Lumryz Tablets
$ALKS
◈ ESEN AI
Granules India has secured First-to-File (FTF) status for a generic version of Lumryz tablets in the United States market. This regulatory milestone provides the company with a 180-day exclusivity window, a meaningful c…
SEEKINGALPHA.COM
·
2026-06-19
NEUTRAL
BULLISH
CORR0.52
Alkermes: "Buy" On Avadel Acquisition And Positive NT2 Data With Alixorexton (NASDAQ:ALKS)
$ALKS
◈ ESEN AI
Alkermes (ALKS) is being positioned as a buy on two fundamental catalysts: the Avadel acquisition and positive clinical data for its pipeline candidate alixorexton. The Avadel deal brings established commercial revenue …
EXPLORE OTHER FILTERS